LONG-TERM TREATMENT OF DUODENAL-ULCER WITH TRIMIPRAMINE - A DOUBLE-BLIND-STUDY

  • 1 January 1982
    • journal article
    • research article
    • Vol. 17  (8) , 1003-1007
Abstract
Sixty-two patients with healed duodenal or prepyloric ulcers completed a double-blind long-term trial with either 25 mg/day of trimipramine (32 patients) or placebo (30 patients). Endoscopy was performed when marked dyspeptic complaints occurred or after a 1-yr follow-up study. Eleven patients in the trimipramine-treated group and 18 patients in the placebo group had relapses, with endoscopically confirmed ulcers or erosions with duodenitis and severe symptoms, revealing a statistically significant difference between the groups in favor of trimipramine. Twenty-one patients (66%) receiving trimipramine and 12 patients (40%) receiving placebo were in remission at the end of the study. The probability of having a relapse increased with the time from start of placebo, but decreased in the group that received trimiparamine. No serious side effects occurred. Twenty-five mg of trimipramine daily reduced significantly the recurrence rate of duodenal ulcer disease, when compared with placebo.